Author

Liliana Ascione

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

54 Primary Progressive Disease and Outcomes with First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Real-World IMDC Analysis

Abstract Background Nivolumab plus ipilimumab (NIVO+IPI) combination therapy is a first-line standard in metastatic renal cell carcinoma (mRCC). Despite durable responses in some patients, over 20% develop primary progressive disease (PPD) at first restaging imaging. In this study, we evaluated clinical factors associa...

É. Ibrahim, Wan-Ling Xie, R. El Hajj Chehade et al. · The Oncologist · 0 citations

Open access Sep 2026

43 DSG2 and NPNT are Elevated in the Plasma of Metastatic Chromophobe RCC and are Associated with Poorer Overall Survival

Abstract Background Chromophobe renal cell carcinoma (ChRCC) is traditionally defined by its unique metabolic reprogramming, including an increase in mitochondrial mass. The mitochondrial plasma proteome of metastatic ChRCC has been recently reported (Steiner et al. Cancers 2026), and we defined a two-protein signature...

Tie-Gang Han, Clara Steiner, Steven Safi et al. · The Oncologist · 0 citations

Open access Sep 2026

19 Dissecting ARNT Expression Patterns in RCC and Association with Outcomes

Abstract Background Hypoxia signaling is a key driver of renal cell carcinoma (RCC) and is mediated by HIF-dependent transcription. ARNT (HIF-1β) is an essential HIF binding partner, but its expression and clinical relevance in RCC are poorly defined. With ARNT inhibitors in development, characterizing ARNT expression...

Yu-Wei Chen, S. Nazari, A. Elliott et al. · The Oncologist · 0 citations